At the J.P. conference Morgan Healthcare Conference 2026 Gilead Sciences CEO Daniel O'Day said the company has seven drugs in the pipeline for HIV.[1][2][3] These drugs include different dosing options, giving Gilead an advantage.[3] Lenacapavir is a twice-yearly injectable HIV prevention drug like PrEP, approved in the US, EU, South Africa, and Zambia.[1][2][8] The first shipments of lenacapavir arrived in Eswatini and Zambia five months after US approval.[1][2][7] Gilead expects deliveries to other countries in sub-Saharan Africa, including the Republic of South Africa, in early 2026.[1][2] By the end of 2025, it plans regulatory filings in 18 countries where approximately 70% of new HIV infections are.[1][2][8] The company will provide non-profit supplies of lenacapavir to at least two million people in low-income countries until generics are available.[1][2] The PURPOSE 1 and 2 studies demonstrated 100% efficacy in cis women and a 96% reduction in HIV incidence across groups.[3]